Advances in available treatments for metastatic renal cell carcinoma affect the prevalence, morbidity, and mortality associated with skeletal-related events (SREs) owing to metastatic bone lesions. A newly published report shows that the prevalence and in-hospital mortality of SRE-associated hospitalizations are decreasing, while the associated costs are increasing.
- Takeshi Yuasa
- Shinji Urakami